// App-Quantinova.ai

2627 : A phase 1 study of the c-Met inhibitor tivantinib (ARQ 197, IND#112603) in children with relapsed or refractory solid tumors: A Childrens Oncology Group study.

Researchers

Presenter

  • James I. Geller

Principal Investigators

  • John Peter Perentesis

  • Susan Blaney

  • Brenda Weigel

  • Charlotte H. Ahern

  • Rachel A. Kudgus

  • Elizabeth Fox

Medical Centers

  • University of Minnesota, Minneapolis, MN

  • Baylor College of Medicine, Houston, TXThe Childrens Hospital of Philadelphia, Philadelphia, PATexas Childrens Cancer Center, Houston, TX

  • Mayo Clinic, Rochester, MN

  • Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Hepatocyte growth factor receptor

Drug/Treatment

  • Tivantinib

  • ARQ 197

Outcome

  • Positive

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01725191

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved